Johnson & Johnson Unit Cordis Corporation Facing Potential US Stent Supply Disruption

WSJ -- Johnson & Johnson's (JNJ) Cordis unit is facing a potential U.S. supply disruption for its Cypher heart stents because Abbott Laboratories (ABT) will soon stop supplying catheters most commonly used to install the tiny devices, Cordis confirmed Thursday.

Back to news